Comparative study of the effects of venlafaxine and duloxetine on chemotherapy-induced peripheral neuropathy
- 196 Downloads
One of the complications of chemotherapy is peripheral neuropathy. Various studies have shown that potent norepinephrine and serotonin reuptake inhibitors such as gabapentin, venlafaxine and duloxetine have therapeutic effects on neuropathy. The aim of this study was to compare the effects of venlafaxine vs. duloxetine on chemotherapy-induced peripheral neuropathy.
In this clinical trial, cancer patients who were suffering from chemotherapy-induced peripheral neuropathy comprised the study population. They were randomly assigned to three pharmacotherapy groups including venlafaxine, duloxetine and placebo. Cranial, sensory, motor neuropathies as well as neuropathic pain were evaluated on day 1, week 2, and week 4 after enrollment.
Grade of cranial, motor, sensory and neuropathic pain decreased significantly in venlafaxine and duloxetine groups. This reduction was more considerable in duloxetine group compared to venlafaxine group (P < 0.05).
Duloxetine seems to be more effective than venlafaxine in decreasing the symptoms of chemotherapy-induced peripheral neuropathy. Duloxetine was more effective than venlafaxine in decreasing motor neuropathy and neuropathic pain grade.
KeywordsChemotherapy-induced neuropathy Venlafaxine Duloxetine
The authors gratefully acknowledge the Research Council of Kermanshah University of Medical Sciences and Clinical Research Development Center, Imam Reza Hospital for the financial support and cooperation. This work (approved research plan No: 95128) was performed in partial fulfillment of the requirements for Med. D. of Avisa Alavi, in Faculty of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.
This study was funded by Research Council of Kermanshah University of Medical Sciences (Grant Number 95128).
Compliance with ethical standards
Conflict of interest
Authors declare that they have no conflict of interest.
All procedures performed in the study involving human participants were in accordance with the ethical standards of the Research Council of Kermanshah University of Medical Sciences and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 9.Biedrzycki BA (2010) Peripheral neuropathy. In: Brown CG (ed) A guide to oncology symptom management. Oncology Nursing Society, Pittsburgh, pp. 405–421Google Scholar
- 12.Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, Shaw JL, Thompson L, Nelson DL, Hemrick-Luecke SK, Wong DT (2001) Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 25(6):871–880CrossRefGoogle Scholar
- 14.Bril V, England JD, Franklin GM et al (2011) Evidence-based guideline: treatment of painful diabetic neuropathy—report of the American association of neuromuscular and electrodiagnostic medicine, the American academy of neurology, and the American academy of physical medicine & rehabilitation. Muscle Nerve 43(6):910–917CrossRefGoogle Scholar
- 15.Dyck PJ (2005) Peripheral neuropathy. Elsevier Inc., AmsterdamGoogle Scholar
- 16.Kautio AL. Chemotherapy-induced neuropathy: prevention and treatment. Helsinki.2012Google Scholar
- 18.Esin E, Yalcin S (2014) Neuropathic cancer pain: what we are dealing with? How to manage it? OncoTargets Ther 7:599–618Google Scholar
- 20.Shahid A, Wilkinson K, Marcu S, Shapiro CM (2011) Brief pain inventory (BPI). InSTOP, THAT and one hundred other sleep scales. Springer, New York. pp 81–88Google Scholar